Evaluation of the anti-angiogenic properties of the new selective αVβ3 integrin antagonist RGDechiHCit

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Santulli, Gaetano ^a   Basilicata, Maria F ^a   De Simone, Mariarosaria ^a   Del Giudice, Carmine ^a   Anastasio, Antonio ^a   Sorriento, Daniela ^a   Saviano, Michele ^b   Del Gatto, Annarita ^b   Trimarco, Bruno ^a   Pedone, Carlo ^a   Zaccaro, Laura ^b   Iaccarino, Guido ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CILENGITIDE; ECHISTATIN; VITRONECTIN RECEPTOR; ANGIOGENESIS INHIBITOR; CYCLOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WISTAR KYOTO RAT; WOUND HEALING IMPAIRMENT; ANGIOGENESIS; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG ANTAGONISM; DRUG SCREENING; ENZYME SPECIFICITY; MALE; NEOPLASM; PATHOLOGY; PHYSIOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; INTEGRIN ALPHAVBETA3; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES, CYCLIC; RATS; RATS, INBRED WKY; SUBSTRATE SPECIFICITY;

EID: 78651314991     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-7     Document Type: Article

References (39)

1. Santulli G, Ciccarelli M, Palumbo G, Campanile A, Galasso G, Ziaco B, Altobelli GG, Cimini V, Piscione F, D'Andrea LD, et al. In vivo properties of the proangiogenic peptide QK. J Transl Med 2009, 7:41. 10.1186/1479-5876-7-41, 2702279, 19505323.
2. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, Burchfield J, Fox H, Doebele C, Ohtani K, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009, 324:1710-1713. 10.1126/science.1174381, 19460962.
3. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22. 10.1038/nrc2748, 20029421.
4. Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh DA. Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol 2003, 162:933-943. 10.1083/jcb.200304105, 2172815, 12952943.
5. Takahashi S, Moser M, Montanez E, Nakano T, Seo M, Backert S, Inoue I, Awata T, Katayama S, Komoda T, Fassler R. The fibronectin RGD motif is required for multiple angiogenic events during early embryonic development. Arterioscler Thromb Vasc Biol 2010, 30:e1. 10.1161/ATVBAHA.108.181164, 19713531.
6. Castel S, Pagan R, Garcia R, Casaroli-Marano RP, Reina M, Mitjans F, Piulats J, Vilaro S. Alpha v integrin antagonists induce the disassembly of focal contacts in melanoma cells. Eur J Cell Biol 2000, 79:502-512. 10.1078/0171-9335-00067, 10961450.
7. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. Embo J 1999, 18:882-892. 10.1093/emboj/18.4.882, 1171181, 10022831.
8. Lu H, Murtagh J, Schwartz EL. The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere). Mol Pharmacol 2006, 69:1207-1215. 10.1124/mol.105.019075, 1462867, 16415178.
9. Bayless KJ, Salazar R, Davis GE. RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am J Pathol 2000, 156:1673-1683. 1876924, 10793078.
10. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996, 85:683-693. 10.1016/S0092-8674(00)81235-0, 8646777.
11. Abumiya T, Lucero J, Heo JH, Tagaya M, Koziol JA, Copeland BR, del Zoppo GJ. Activated microvessels express vascular endothelial growth factor and integrin alpha(v)beta3 during focal cerebral ischemia. J Cereb Blood Flow Metab 1999, 19:1038-1050. 10.1097/00004647-199909000-00012, 10478656.
12. Mahabeleshwar GH, Feng W, Reddy K, Plow EF, Byzova TV. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res 2007, 101:570-580. 10.1161/CIRCRESAHA.107.155655, 2723825, 17641225.
13. Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL, Arnaout MA. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002, 296:151-155. 10.1126/science.1069040, 11884718.
14. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 1991, 291:50-54. 10.1016/0014-5793(91)81101-D, 1718779.
15. Schottelius M, Laufer B, Kessler H, Wester HJ. Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res 2009, 42:969-980. 10.1021/ar800243b, 19489579.
16. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 1998, 140:1255-1263. 10.1083/jcb.140.5.1255, 2132684, 9490736.
17. Bai J, Zhang J, Wu J, Shen L, Zeng J, Ding J, Wu Y, Gong Z, Li A, Xu S, et al. JWA regulates melanoma metastasis by integrin alpha(V)beta(3) signaling. Oncogene 2010, 29:1227-1237. 10.1038/onc.2009.408, 19946336.
18. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 2003, 39:917-926. 10.1016/S0959-8049(03)00057-1, 12706360.
19. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A, Goodman SL, Kessler H. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 1999, 42:3033-3040. 10.1021/jm970832g, 10447947.
20. Del Gatto A, Zaccaro L, Grieco P, Novellino E, Zannetti A, Del Vecchio S, Iommelli F, Salvatore M, Pedone C, Saviano M. Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. J Med Chem 2006, 49:3416-3420. 10.1021/jm060233m, 16722662.
21. Zannetti A, Del Vecchio S, Iommelli F, Del Gatto A, De Luca S, Zaccaro L, Papaccioli A, Sommella J, Panico M, Speranza A, et al. Imaging of alphavbeta3 expression by a bifunctional chimeric RGD peptide not cross-reacting with alphavbeta5. Clin Cancer Res 2009, 15:5224-5233. 10.1158/1078-0432.CCR-08-3270, 19671851.
22. Ciccarelli M, Cipolletta E, Santulli G, Campanile A, Pumiglia K, Cervero P, Pastore L, Astone D, Trimarco B, Iaccarino G. Endothelial beta2 adrenergic signaling to AKT: role of Gi and SRC. Cell Signal 2007, 19:1949-1955. 10.1016/j.cellsig.2007.05.007, 17629454.
23. Iaccarino G, Ciccarelli M, Sorriento D, Cipolletta E, Cerullo V, Iovino GL, Paudice A, Elia A, Santulli G, Campanile A, et al. AKT participates in endothelial dysfunction in hypertension. Circulation 2004, 109:2587-2593. 10.1161/01.CIR.0000129768.35536.FA, 15136501.
24. Illario M, Cavallo AL, Monaco S, Di Vito E, Mueller F, Marzano LA, Troncone G, Fenzi G, Rossi G, Vitale M. Fibronectin-induced proliferation in thyroid cells is mediated by alphavbeta3 integrin through Ras/Raf-1/MEK/ERK and calcium/CaMKII signals. J Clin Endocrinol Metab 2005, 90:2865-2873. 10.1210/jc.2004-1520, 15687337.
25. Iaccarino G, Smithwick LA, Lefkowitz RJ, Koch WJ. Targeting Gbeta gamma signaling in arterial vascular smooth muscle proliferation: a novel strategy to limit restenosis. Proc Natl Acad Sci USA 1999, 96:3945-3950. 10.1073/pnas.96.7.3945, 22400, 10097143.
26. Iaccarino G, Ciccarelli M, Sorriento D, Galasso G, Campanile A, Santulli G, Cipolletta E, Cerullo V, Cimini V, Altobelli GG, et al. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res 2005, 97:1182-1189. 10.1161/01.RES.0000191541.06788.bb, 16239589.
27. Ciccarelli M, Santulli G, Campanile A, Galasso G, Cervero P, Altobelli GG, Cimini V, Pastore L, Piscione F, Trimarco B, Iaccarino G. Endothelial alpha1-adrenoceptors regulate neo-angiogenesis. Br J Pharmacol 2008, 153:936-946. 10.1038/sj.bjp.0707637, 2267280, 18084315.
28. Sorriento D, Ciccarelli M, Santulli G, Campanile A, Altobelli GG, Cimini V, Galasso G, Astone D, Piscione F, Pastore L, et al. The G-protein-coupled receptor kinase 5 inhibits NFkappaB transcriptional activity by inducing nuclear accumulation of IkappaB alpha. Proc Natl Acad Sci USA 2008, 105:17818-17823. 10.1073/pnas.0804446105, 2584738, 19008357.
29. Sorriento D, Santulli G, Fusco A, Anastasio A, Trimarco B, Iaccarino G. Intracardiac Injection of AdGRK5-NT Reduces Left Ventricular Hypertrophy by Inhibiting NF-{kappa}B-Dependent Hypertrophic Gene Expression. Hypertension 2010, 56:696-704. 10.1161/HYPERTENSIONAHA.110.155960, 20660817.
30. Santulli G, Illario M, Palumbo G, Sorriento D, Cipolletta E, Trimarco V, Del Giudice C, Ciccarelli M, Trimarco B, Iaccarino G. CaMK4 partecipates in the settings of the hypertensive phenotype: a human genome wide analysis supported by animal model. Eur Heart J 2009, 30(Suppl.1):161.
31. Astrof S, Hynes RO. Fibronectins in vascular morphogenesis. Angiogenesis 2009, 12:165-175. 10.1007/s10456-009-9136-6, 2716138, 19219555.
32. Zaccaro L, Del Gatto A, Pedone C, Saviano M. Peptides for tumour therapy and diagnosis: current status and future directions. Curr Med Chem 2009, 16:780-795. 10.2174/092986709787549307, 19275595.
33. Verbisck NV, Costa ET, Costa FF, Cavalher FP, Costa MD, Muras A, Paixao VA, Moura R, Granato MF, Ierardi DF, et al. ADAM23 negatively modulates alpha(v)beta(3) integrin activation during metastasis. Cancer Res 2009, 69:5546-5552. 10.1158/0008-5472.CAN-08-2976, 19549921.
34. Laitinen I, Saraste A, Weidl E, Poethko T, Weber AW, Nekolla SG, Leppanen P, Yla-Herttuala S, Holzlwimmer G, Walch A, et al. Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. Circ Cardiovasc Imaging 2009, 2:331-338. 10.1161/CIRCIMAGING.108.846865, 19808614.
35. Furundzija V, Fritzsche J, Kaufmann J, Meyborg H, Fleck E, Kappert K, Stawowy P. IGF-1 increases macrophage motility via PKC/p38-dependent alphavbeta3-integrin inside-out signaling. Biochem Biophys Res Commun 2010, 394:786-791. 10.1016/j.bbrc.2010.03.072, 20230795.
36. Vanderslice P, Woodside DG. Integrin antagonists as therapeutics for inflammatory diseases. Expert Opin Investig Drugs 2006, 15:1235-1255. 10.1517/13543784.15.10.1235, 16989599.
37. Tani N, Higashiyama S, Kawaguchi N, Madarame J, Ota I, Ito Y, Ohoka Y, Shiosaka S, Takada Y, Matsuura N. Expression level of integrin alpha 5 on tumour cells affects the rate of metastasis to the kidney. Br J Cancer 2003, 88:327-333. 10.1038/sj.bjc.6600710, 2377056, 12610521.
38. Crawford TN, Alfaro DV, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev 2009, 5:8-13. 10.2174/157339909787314149, 19199892.
39. Santulli RJ, Kinney WA, Ghosh S, Decorte BL, Liu L, Tuman RW, Zhou Z, Huebert N, Bursell SE, Clermont AC, et al. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J Pharmacol Exp Ther 2008, 324:894-901. 10.1124/jpet.107.131656, 18083913.